LUCD vs OSUR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LUCD exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness in profitability, leverage, and operating efficiency. The company suffers from catastrophic operating margins (-931.58%) and negative shareholder equity (P/B of -3.87), suggesting a precarious balance sheet. While revenue growth remains positive at 25.6%, there is a massive disconnect between the fundamental decay and the 'Strong Buy' analyst consensus. The valuation is unjustifiable on a data-driven basis, with a Price/Sales ratio of 46.34 for a company consistently missing earnings estimates.
OSUR presents a stark contrast between a fortress-like balance sheet and a deteriorating business model. While the Piotroski F-Score of 6/9 indicates stable financial health and the company maintains exceptional liquidity (Current Ratio 6.58) with negligible debt, the operational metrics are alarming. Revenue has contracted by 28.5% YoY, and profit margins are deeply negative at -59.76%. Despite trading at a significant discount to book value (P/B 0.67), the lack of growth and consistent earnings misses suggest a value trap.
Compare Another Pair
Related Comparisons
LUCD vs OSUR: Head-to-Head Comparison
This page compares Lucid Diagnostics Inc. (LUCD) and OraSure Technologies, Inc. (OSUR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.